12/4
09:44 pm
regn
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory [Yahoo! Finance]
Low
Report
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory [Yahoo! Finance]
12/4
02:03 pm
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Canaccord Genuity Group Inc. from $850.00 to $1,057.00. They now have a "buy" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Canaccord Genuity Group Inc. from $850.00 to $1,057.00. They now have a "buy" rating on the stock.
12/4
09:04 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at BMO Capital Markets from $725.00 to $850.00. They now have an "outperform" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at BMO Capital Markets from $725.00 to $850.00. They now have an "outperform" rating on the stock.
12/3
08:44 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $767.00 price target on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $767.00 price target on the stock.
12/1
07:00 am
regn
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
Medium
Report
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
12/1
07:00 am
regn
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
Medium
Report
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
11/28
10:28 am
regn
Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500? [Yahoo! Finance]
Low
Report
Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500? [Yahoo! Finance]
11/28
03:37 am
regn
The Bull Case For Regeneron (REGN) Could Change Following European Approval of Dupixent for CSU Patients [Yahoo! Finance]
Low
Report
The Bull Case For Regeneron (REGN) Could Change Following European Approval of Dupixent for CSU Patients [Yahoo! Finance]
11/26
06:43 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Hsbc Global Res to a "strong-buy" rating.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Hsbc Global Res to a "strong-buy" rating.
11/25
09:29 pm
regn
Regeneron Pharmaceuticals (REGN): Examining Valuation After Recent Share Price Momentum [Yahoo! Finance]
Low
Report
Regeneron Pharmaceuticals (REGN): Examining Valuation After Recent Share Price Momentum [Yahoo! Finance]
11/25
01:00 am
regn
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Medium
Report
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
11/24
11:00 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $798.00 price target on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $798.00 price target on the stock.
11/24
10:12 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Scotiabank from $650.00 to $770.00. They now have a "sector perform" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Scotiabank from $650.00 to $770.00. They now have a "sector perform" rating on the stock.
11/24
08:06 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) is now covered by analysts at HSBC Holdings plc. They set a "buy" rating and a $890.00 price target on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) is now covered by analysts at HSBC Holdings plc. They set a "buy" rating and a $890.00 price target on the stock.
11/22
05:33 am
regn
Are Shares of Regeneron Attractive After Recent Surge on Clinical Trial Success? [Yahoo! Finance]
Low
Report
Are Shares of Regeneron Attractive After Recent Surge on Clinical Trial Success? [Yahoo! Finance]
11/21
01:00 pm
regn
Are Wall Street Analysts Bullish on Regeneron Pharmaceuticals Stock? [Yahoo! Finance]
Low
Report
Are Wall Street Analysts Bullish on Regeneron Pharmaceuticals Stock? [Yahoo! Finance]
11/20
10:42 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Wells Fargo & Company from $615.00 to $700.00. They now have an "equal weight" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Wells Fargo & Company from $615.00 to $700.00. They now have an "equal weight" rating on the stock.
11/20
07:34 am
regn
Regeneron's Eylea franchise boosted by pair of FDA approvals [Yahoo! Finance]
Low
Report
Regeneron's Eylea franchise boosted by pair of FDA approvals [Yahoo! Finance]
11/19
04:45 pm
regn
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications [Yahoo! Finance]
Neutral
Report
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications [Yahoo! Finance]
11/19
04:10 pm
regn
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
Medium
Report
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
11/19
01:21 pm
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
07:00 am
regn
Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation
Medium
Report
Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation
11/17
05:55 pm
regn
Sepsis Market is Projected to Boost at a CAGR of 5.1% in the US During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]
Low
Report
Sepsis Market is Projected to Boost at a CAGR of 5.1% in the US During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]
11/17
01:27 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at
Wall
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at
Wall
11/14
10:32 am
regn
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? [Yahoo! Finance]
Low
Report
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? [Yahoo! Finance]